ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2020
Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Efficacy and safety of integrated traditional Chinese and Western medicine against COVID-19: A systematic review and meta-analysis.Phytotherapy research : PTR · 2022Pooled it
- Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022Pooled it
- Chinese herbal medicine ("3 medicines and 3 formulations") for COVID-19: rapid systematic review and meta-analysis.Journal of evaluation in clinical practice · 2022Pooled it
- Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies.Frontiers in pharmacology · 2022Pooled it
- Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis.PloS one · 2021Pooled it
- A Triple-blind randomized controlled trial on the effects of turmeric versus ginger on inflammatory biomarkers in patients with COVID-19.Scientific reports · 2025Trial
- Molecular Roadmap of COVID-19: From Viral Entry to Therapeutic Targets.Chemistry & biodiversity · 2026Review
- Research progress in the inhibitory mechanisms of traditional Chinese medicine therapies against influenza A.Frontiers in immunology · 2026Review
- A new evaluation methodology study - Integrating 'ancient literature - clinical research - expert consensus' firstly proposes eight elements for taking Chinese medicine decoctions.Frontiers in pharmacology · 2025Article
- Article
- Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.Infectious diseases of poverty · 2024Article
- Article
- Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.Medicines (Basel, Switzerland) · 2024Review
- Bibliometric analysis and key messages of integrating Chinese and Western Medicine for COVID-19.Heliyon · 2024Article
- Role of innate immunity in SARS-CoV-2 infection.Biosafety and health · 2023Review
- Article
- Liver in infections: a single-cell and spatial transcriptomics perspective.Journal of biomedical science · 2023Review
- Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.Acta pharmaceutica Sinica. B · 2023Review
- Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19.Journal of biomedical science · 2023Review
- New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches.Chinese herbal medicines · 2023Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19)
methodsIn this study, 63 patients with confirmed COVID-19 were analyzed. During the first 14 days of hospitalization, patients with deteriorating symptoms were administered QPD along with Western medicine therapy (the antiviral medicine selected from interferon, lopinavir, or arbidol). The clinical characteristics and blood laboratory indices (blood routine, inflammatory factors, and multi-organ biochemical indices) were examined, and the total lung severity scores were evaluated in each patient by reviewing chest computed tomography before treatment and at the end of treatment.
resultsBefore QPD treatment, the combined treatment group showed higher blood C-reactive protein levels and more severe pulmonary inflammation and clinical symptoms than the Western medicine treatment group. Both groups met the discharge criteria after a similar length of hospitalization. At the end of treatment, circulating white blood cells, total lymphocyte count, and glutamic-oxaloacetic transaminase levels improved dramatically in both groups (P < 0.05). In contrast, C-reactive protein, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels were improved only in the combined treatment group (P < 0.05), and C-reactive protein and creatine kinase were the most pronounced (P < 0.01). Compared with baseline, at the end of treatment, the proportion of patients with normal values of C-reactive protein, total lymphocyte count, and lactate dehydrogenase were increased in the combined treatment group (P < 0.05), whereas no significant difference was observed in the Western medicine treatment group (P > 0.05).
conclusionThe combination of QPD with Western medicine demonstrated significant anti-inflammatory effects compared with those of only Western medicine in patients with mild and moderate COVID-19; however, neither mortality nor length of hospitalization was affected. Moreover, the combined treatment tended to mitigate the extent of multi-organ impairment. Long-term randomized controlled trials with follow-up evaluations are required to confirm the results presented here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.